Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K20/00—Accessory food factors for animal feeding-stuffs
  • A23K20/10—Organic substances
  • A23K20/142—Amino acids; Derivatives thereof
  • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
  • A61K38/1706—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/10—Antimycotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
  • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides

Definitions

• the present invention is related to the field of biotechnology, specifically with the obtention of antimicrobial peptides and their use for the control of pathogens.
• antimicrobial peptides When antimicrobial peptides are applied, the diseases produced by pathogens can be effectively controlled.
• these peptides contribute to potentiate the immune response induced by various antigens comprised in vaccines.
• the MPAs are divided into five categories, based on their amino acid composition and structure. These categories include anionic peptides, linear peptides with an amphipathic ⁇ -helix structure, cationic peptides enriched with specific amino acids, peptide fragments and tank peptides that form intramolecular bonds (Brogden (2005) Nat Rev Microbiol. 3: 238-50; Boman (2000) Immunol Rev.173: 5-16). Anionic peptides are produced in millimolar concentrations, require zinc as a cofactor, and show antimicrobial activity against Gram-positive and Gram-negative bacteria.
• Linear and cationic peptides with an antipathic ⁇ -helix structure have less than 40 amino acids and have a three-dimensional structure with a hinge region in the middle portion. Although their structure is disordered in solution, these molecules adopt a secondary structure of ⁇ -helix when they are in contact with the membranes (Brogden (2005) Nat Rev Microbiol. 3: 238-50).
• the other group consisting of peptides Linear cationic enriched with specific amino acids, 'does not possess cysteine residues, so said peptides have a very flexible structure in solution (Brogden (2005) Nat Rev Microbiol. 3: 238-50).
• the fourth group comprises loaded peptides that are fragments from larger proteins.
• the fifth group of peptides is composed of approximately 380 members, containing 6 conserved cysteine residues that form intramolecular bonds and a ⁇ -sheet structure (Brogden (2005) Nat Rev Microbiol. 3: 238-50). In this group are the defensins and hepcidin (Boman et al. (2000) Immunol Rev. 173: 5-16). '
• MPAs are commonly classified by variations in structural characteristics, there are some traits that are common to most of these peptides. For example, they generally have less than 60 amino acids, have a broad spectrum of antimicrobial activity under physiological conditions, and have a positive charge (Zasloff (2002) Nature 415: 389-395). Most MPAs adopt an amphipathic structure that contributes to the mechanism of action of these peptides, based on their interaction with the lipid cell membrane of pathogens such as bacteria and enveloped viruses (Shai (2002) Biopolymers 66: 236-48; Jelinek and Kolusheva (2005) Curr. Protein Pept. Sci. 6: 103-14). This interaction causes rapid destabilization / permeabilization of the pathogen's lipid membrane.
• MPAs can inhibit the synthesis of cell wall, nucleic acids, proteins and even inhibit enzymatic activity (Brogden et al. (2005) Nat. Immunol. 6: 558- 64; Campagna et al. (2007) Biochemistry 46: 1771-8).
• an important problem to solve is to achieve new antimicrobial products, of a protein nature, capable of efficiently controlling a wide range of pathogens and also having an impact on innate and adaptive immunity, aspects of great importance in medicine and veterinary medicine. , including aquaculture. Explanation of the invention.
• the present invention solves the aforementioned problem, by providing a new alternative for the control and treatment of pathogen infections, including those caused by bacteria, viruses or fungi.
• antimicrobial peptides that are identified as SEQ ID No. 1, 2 and 3 are reported.
• the amino acid sequences comprising in their amino acid sequence those that are identified as SEQ are also object of the invention. ID No.1, 2 and 3, or an amino acid sequence with at least 80% identity with the peptides identified as SEQ ID No. 1, 2 or 3.
• Oreochromycin I From protein extracts of tilapia gills (Oreochromis niloticus) three peptides were isolated and sequenced, which were called Oreochromycin I, Oreochromycin II and Oreochromycin III, which have not been reported in the literature and are denoted in the invention as SEQ ID No. 1, 2 and 3. These peptides possess antimicrobial effect against Gram-positive, Gram-negative bacteria, viruses and fungi. In addition to being obtained by isolation from their natural source, the peptides of the invention can be obtained by chemical synthesis or via recombinant deoxyribonucleic acid (DNA).
• DNA deoxyribonucleic acid
• the antimicrobial peptides thereof are obtained from expression in bacteria, yeasts or cells of higher organisms. Said antimicrobial peptides can be expressed in different host systems, and isolated from them. In a particular embodiment, the antimicrobial peptides can be expressed in yeasts. In a preferred embodiment, expression by the recombinant DNA pathway is performed in Pichia pastoris, preferably in the culture supernatant. The antimicrobial peptides of the invention can also be expressed in bacteria. In another preferred embodiment, expression by the recombinant DNA pathway is performed in Escherichia coli. From the hosts, the peptides of the invention can be obtained by protein isolation techniques that are widely known to those well versed in this field of art, such as chromatographic techniques, washing the cell precipitate, and others.
• antimicrobial peptides offer advantages, compared to other antimicrobial agents, because they are less than 5 KDa in size, so they are better absorbed through the skin and mucous membranes of aquatic organisms because they are applied by immersion, which is a route of administration with cost and handling advantages for aquaculture, and with low pollution rates. Another advantage is to stimulate innate and adaptive immune activity, and increase resistance to infections by pathogens.
• oligonucleotides were designed to amplify, by polymerase chain reaction (abbreviated polymerase chain reaction, abbreviated PCR), the nucleotide sequence coding for each of the mature peptides. Therefore, a nucleic acid characterized by comprising a nucleic acid sequence selected from the group consisting of SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 is the subject of this invention.
• Another object of the present invention is a nucleic acid encoding peptides comprising the amino acid sequences identified as SEQ ID No. 1, 2 and 3, or an amino acid sequence with at least 80% identity with the peptides identified as SEQ ID No. 1, 2 or 3.
• the invention also provides a composition for the control of pathogens comprising the peptides identified as SEQ ID No.1, 2 and 3 or peptides with 80% identity with the peptides identified as SEQ ID No.1, 2 or 3.
• the antimicrobial peptides whose sequences are claimed can be used for the control of a wide variety of pathogens such as: bacterial pathogens (Aeromonas, Pseudomonas, Corynebacteria, Enterobacteria, Haemophilus, Mycobacteria , Nocardia, Myxobacteria, Streptomyces and Vibrio, among others); viral pathogens (infectious hematopoietic necrosis virus, infectious pancreatic necrosis virus, hemorrhagic septicemia virus, iridovirus, carp hemorrhagic virus, carp spring viremia virus, hirame rabdovirus or rabdovirus snakehead virus, lymphocystitis, infectious salmon anemia virus, among others); fungi (Saprolegnia, Achlya, Ychthyosporidium hoferi, among others).
• pathogens such as: bacterial pathogens (Aero
• the Oreochromycin I, Oreochromycin II and Oreochromycin III peptides, as well as the peptides having at least 80% sequence identity with them are formulated in compositions that are used for the control of pathogens in different living organisms, including aquatic organisms and mammals. Such compositions are administered both preventively and as a therapeutic way to control pathogens.
• the routes of administration comprise all those routes that are employed in the administration of drugs in humans, and of medications or additives in the case of animals, and which are well known to those skilled in this field of the art.
• the pathogen control compositions of the invention are administered orally, parenterally, or by immersion baths.
• a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 2 and SEQ ID No. 3, or an amino acid sequence with at least 80% identity with SEQ ID No. 1, SEQ ID No. 2 or SEQ ID No. 3 to make a pathogen control composition.
• Another aspect thereof is to provide a method for the control of pathogens in living organisms that is characterized in that an effective amount of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. is administered. 2 and SEQ ID No. 3, or an amino acid sequence with at least 80% identity with SEQ ID No. 1, SEQ ID No. 2 or SEQ ID No. 3 to said organism.
• the peptides of the invention are applied to the fish by periodic injections, at concentrations between 0.1 and 10 pg / fish, by immersion baths with intervals of 1-15 days (on alternate or consecutive days) in fresh water or seawater, at a concentration of the peptide between 0.01 and 0.1 mg / L of water. They can also be applied to fish as an additive in feed, at an approximate concentration of 50-750 pg of peptide / kg of feed. In all cases, a significant increase in resistance to diseases caused by pathogens is obtained, whether caused by viruses, bacteria or fungi, among others.
• the peptides provided by this invention are useful as molecular adjuvants for vaccines.
• the term "molecular adjuvant” refers to a molecule of a protein nature capable of modulating the immune response against a vaccine antigen, producing an increase thereof.
• the invention also contemplates a vaccine composition characterized in that it comprises a peptide comprising a sequence of amino acids selected from the group consisting of SEQ ID No. 1, SEQ ID No. 2 and SEQ ID No. 3, or an amino acid sequence with at least 80% identity with SEQ ID No. 1, SEQ ID No. 2 or SEQ ID No. 3, as a molecular adjuvant, and a vaccine antigen.
• Another aspect thereof is to provide a method to increase the immune response against a vaccine antigen that is characterized in that a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 2 and SEQ is used ID No. 3, or an amino acid sequence with at least 80% identity with SEQ ID No. 1, SEQ ID No. 2 or SEQ ID No. 3, as a molecular adjuvant in a vaccine.
• Figure 1 Cloning strategy of the antimicrobial peptides of the invention in expression vectors in E. coli (Fig. 1A) and in yeast P. pastoris (Fig. 1 B).
• Figure 2. Purification of antimicrobial peptides from the culture supernatant of P. pastoris (Fig. 2A) and rupture supernatant of E. coli (Fig. 2B). Lane 1: Oreochromycin I; Lane 2: Oreochromycin II; Lane 3: Oreochromycin III.
• FIG. 3 Antiviral activity of the Oreochromycin I, Oreochromycin II and Oreochromycin III antimicrobial peptides.
• EPC cells epidermaloma papulosum cyprinid
• pTargeT-Oreochromycin I, pTargeT-Oreochromycin II and pTargeT-Oreochromycin III or pTargeT as control.
• FIG. 4 Saturation curve of the binding of the Oreochromycin I, Oreochromycin II, Oreochromycin III to Lipopolysaccharide (LPS) antimicrobial peptides.
• the concentrations that produce 50% of the binding (EC50) of the Oreochromycin I, Oreochromycin II and Oreochromycin III peptides were 1.23 ⁇ ; 1, 41 ⁇ and 2.99 ⁇ , respectively.
• Figure 6. Total immunoglobulin (IgG) titers induced by the immunization of mice with ovalbumin (OVA) co-administered with the peptides Oreochromycin I, Oreochromycin II and Oreochromycin III. Four test groups were established, of 6 animals each. The negative control group (phosphate buffered saline (PBS) / OVA) was inoculated intraperitoneally, on days 0 and 7 with a dose of 6 g of OVA in 0.2 ml_ of PBS.
• PBS phosphate buffered saline
• OVA phosphate buffered saline
• FIG. 7 Total IgG titers (A), IgG1 and IgG2a (B) induced by immunization of mice with OVA co-administered with the Oreochromycin I, II and III antimicrobial peptides.
• mice Male Balb / c mice (8 / group) were immunized by intraperitoneal injection on days 0 and 14 with OVA alone (5 mg / animal) or in combination with peptides at the doses of 0,238x10 20 molecules / animal (equivalent to 0.1, 0.12 and 0.14 ⁇ g / animal for Oreochromycin I, II and III, respectively) and 2.38x10 20 molecules / animal (equivalent to 1, 1, 2 and 1, 4 ⁇ g / abnormal for Oreochromycin I, II and III, respectively).
• the negative control group was injected with 0.1 mL of 1X PBS.
• the humoral immune response specific for OVA total IgG was analyzed at 14 and 21 days after the first immunization.
• the specific antibody titers of lgG1 and lgG2a were analyzed at 21 days after the first immunization. OVA specific antibody titers were determined by ELISA.
• FIG. 8 IFN- ⁇ secretion by spleen cells isolated from immunized animals.
• the concentration of IFN- ⁇ in the supernatant of splenocytes stimulated with OVA (10 ⁇ g / mL) is represented on the Y axis.
• He Statistical analysis of the data was performed using an ANOVA and a Bonferroni multiple comparisons test (*: p ⁇ 0.05; ***: p ⁇ 0.001).
• FIG. 9 Titles of IgM induced by immunization of tilapia (O. niloticus) with the MY32 protein co-administered with the antimicrobial peptide Oreochromycin I.
• Fish (10 fish / group) were immunized by intraperitoneal injection on days 0 and 14
• the negative control group was injected with 0.3 mL of 1X PBS.
• the humoral immune response specific for MY32 was analyzed at 14, 21 and 28 days after the first immunization.
• Statistical analysis of the data was performed using an ANOVA and a Newman-Keuls multiple comparisons test (* indicates p ⁇ 0.05).
• Example 1 Isolation and purification of antimicrobial peptides from extracts of tilapia gills.
• the filaments of tilapia gills were macerated in liquid nitrogen and the resulting powder was heated at 100 ° C in a thermostated bath for 10 min and allowed to cool.
• Protein was extracted by adding 150 mL of a solution composed of 2M HCI, 10% (v / v) formic acid, 2% (w / v) NaCI and 1% (v / v) of trichloroacetic acid, followed by homogenization for 1-2 min. The homogenate was centrifuged at 20,000 x g for 30 min, the supernatant was adjusted to pH 4.0 and filtered.
• the resulting filtrate was used as an acid extract and applied to a Sep-Pak C18 column (Waters, Milford, MA, USA). After washing with 0.1% trifluoroacetic acid, the fraction corresponding to the peptides was eluted with 80% acetonitrile / 0.1% trifluoroacetic acid. The eluate was dried and dissolved in 1 M acetic acid and adsorbed to a matrix of SP-Sephadex C-25. Successive elution steps with 1M acetic acid, 2M pyridine and 2M pyridine / acetic acid (pH 5.0) yielded five fractions. Each fraction was performed with antimicrobial activity and fraction 2 was chosen for further purification steps.
• the selected fraction was lyophilized and dissolved in 40% acetonitrile containing 0.1% trifluoroacetic acid.
• An aliquot of the solution was applied to a TSKgel G2000SW column (gel filtration, high efficiency liquid chromatography (HPLC)) and eluted with 40% acetonitrile containing 0.1% trifluoroacetic acid.
• HPLC gel filtration, high efficiency liquid chromatography
• the same fraction was repeatedly injected into the column, and the resulting fraction with a molecular weight of less than 5 kDa and with antimicrobial activity was lyophilized and subjected to reverse phase chromatography (RP-HPLC) and Mass spectrometry (ESI- MS).
• RP-HPLC reverse phase chromatography
• ESI- MS Mass spectrometry
• the molecular weight of said fraction was determined by sodium tricine-Dodecyl sulfate gel electrophoresis (16.5% T / 3% C) (Tricine-sodium dodecyl sulfate polyacrylamide gel electrophoresis, abbreviated Tricine-SDS-PAGE).
• the separation of the proteins by HPLC was carried out in a Hewlett-Packard HP1 100 system.
• Solvent A was 5% acetonitrile containing 0.1% trifluoroacetic acid and solvent B was 80% acetonitrile containing 0.085% acid trifluoroacetic Fraction A was reconstituted with solvent A and subjected to RP-HPLC on a C8-3 column (4.6x150 mm).
• the gradient was 0-2 min 0% solvent B, 2-5 min 0-20% solvent B, 5-55 min 20-47% solvent B, and 55-80 min 47-100% solvent B.
• the resulting fractions that showed antimicrobial activity lyophilized, reconstituted in 5mM KH 2 PO 4 / H3PO 4 (pH 3.0) containing 25% acetonitrile and loaded onto a PolySulfoethyl Aspartamide column (4.6 x 200 mm).
• the fractions were eluted with a linear gradient of KCI.
• the molecular weights of the fractions that showed the highest antimicrobial activity were: 2527.3, 2981.9 and 3654.6 Da. These peptides were called Oreochromycin I, II and III, respectively.
• amino acid sequences of each of the peptides with antimicrobial activity were determined, and are hereinafter identified as SEQ ID No. 1, 2 and 3, respectively.
• an analysis of the sequences was performed using the BlastX programs and it was found that these peptides were not previously reported.
• Example 2 Construction of vectors for the expression of antimicrobial peptides intracellularly in E. coli and extracellularly in P. pastoris yeast.
• RNA total ribonucleic acid
• tilapia gills O. niloticus
• the reactions were carried out following the instructions described in the "Reverse Transcription System” kit (Promega, United States). Briefly, 4 pg of total RNA was placed in a nuclease-free microcentrifuge tube and incubated for 10 minutes at 70 ° C.
• nucleotide sequences encoding the mature region of the antimicrobial peptides were amplified (by PCR), using degenerate synthetic oligonucleotides, designed from the amino acid sequence of each peptide. In all cases a DNA band of the expected size was obtained. The bands were purified from the agarose gel and inserted into the commercial vector pGEM-TEasy (Promega) for sequencing. DNA sequences encoding the peptides are identified as SEQ ID No. 4, 5 and 6.
• DNA sequences encoding the antimicrobial peptides were inserted into the expression vector in E. coli pAR 3040, using the Ndel / restriction sites.
• the pPS9 or pPS10 vectors and specific oligonucleotides that recognize the 5 'and 3' sequences of each of the peptides and possess enzyme recognition sites were used of restriction
• the cloning in the pPS9 vector the Ncol and Spel sites were used, and for the cloning in the pPS10 vector the Nael and Spel sites were used.
• Plasmids were linearized before transforming the strain of MP36 from P. pastoris. The transformation was carried out by electroporation.
• the MP36 strain is a His3 auxotrophic mutant, which acquires a His + phenotype after transformation.
• Transforming clones were identified by Dot Blot. Using the Southern Blot technique, it was determined in which of these clones integration had occurred by replacing the AOX1 gene of P. pastoris with the expression cassette of the recombinant plasmid, which corresponds to a Mut s phenotype (low methanol utilization) and His +.
• the P. pastoris yeast secretes low levels of own proteins and its culture medium does not need protein supplements, so it can be expected that a heterologous protein that is secreted to the extracellular medium, constitutes the majority of the total protein in the culture medium (more than 80%) (Tschopp and col. (1987) Bio / Technology, 5: 1305-1308).
• the expression of the peptides in P. pastoris was carried out in 5 liter air fresheners, by adding methanol to the culture medium.
• the expression of the recombinant peptides and their integrity were checked by Tricine-SDS-PAGE and ESI-MS.
• Example 3 Purification and assay of the biological activity of antimicrobial peptides.
• Antimicrobial peptides obtained recombinantly were purified from the E. coli rupture supernatant or the P. pastoris culture supernatant.
• dialysis was performed in 25 mM sodium acetate at pH 4.5, with a membrane with a pore size of 1 kDa.
• the dialysis product was passed through a CM-Sepharosa Fast-flow cation exchange resin, equilibrated with 25 mM sodium acetate (pH 4.5); and the proteins were eluted with 1 M sodium chloride, 50 mM Tris (pH 7.6).
• Fractions containing the peptides were collected and concentrated, using an ultracentrifugation system with a membrane with a pore size of 1 kDa. For the detection, a wavelength of 254 nm was used. Purification was checked by Tricine-SDS-PAGE and the proteins were visualized by staining with Coomassie Blue ( Figure 2).
• the peptides of the invention were also obtained by chemical synthesis, using the procedures known to those skilled in this field of the art.
• the antimicrobial activity of the peptides obtained was determined by the microdilution method. To determine the minimum inhibitory concentration (of the English minimal inhibitory concentration, abbreviated MIC), each of the peptides is given made serial dilutions 1: 2.
• Example 4 Determination of resistance to infection by Aeromonas hydrophila in tilapia previously treated with antimicrobial peptides. Administration of peptides by intraperitoneal injection
• the usefulness of antimicrobial peptides to increase disease resistance in vivo was evaluated.
• 130 tilapia were used (O. niloticus) of body mass of approximately 10 g, which were randomly distributed in thirteen experimental groups of ten animals each. This trial was conducted with the objective of determining the minimum treatment time required to increase the survival of the fish against a challenge with A. hydrophila.
• Each peptide was administered at a concentration of 1 ⁇ g per fish, by intraperitoneal injection, for 2, 4, 8 and 15 days.
• An additional group was placed to which PBS was administered as a control.
• the experimental groups were the following: Group 1: PBS.
• Group 2 Oreochromycin I Peptide administered for 2 consecutive days
• Group 3 Oreochromycin I Peptide administered for 4 consecutive days.
• Group 4 Oreochromycin I Peptide administered for 8 consecutive days.
• Group 5 Oreochromycin I Peptide administered for 15 consecutive days.
• Group 6 Oreochromycin II Peptide administered for 2 consecutive days.
• Group 7 Oreochromycin II Peptide administered for 4 consecutive days.
• Group 8 Oreochromycin II Peptide administered for 8 consecutive days.
• Group 9 Oreochromycin II Peptide administered for 15 consecutive days.
• Group 10 Oreochromycin III Peptide administered for 2 consecutive days.
• Group 1 1 Oreochromycin III Peptide administered for 4 consecutive days.
• Group 12 Oreochromycin III Peptide administered for 8 consecutive days.
• Group 13 Oreochromycin III Peptide administered for 15 consecutive days.
• RPS (%) (% of control mortality -% of treatment mortality) / (% of control mortality) x100
• a second trial was performed to determine the optimal dose of peptide required to increase fish survival after a challenge with A. hydrophila. They were used 130 tilapia (O. niloticus), of body mass of approximately 10 g, which were randomly distributed in thirteen experimental groups of ten animals each.
• Each peptide was administered at a concentration of 0.5; one ; 5 and 10 ⁇ g per fish, for 15 days.
• the experimental groups were the following:
• Group 2 Oreochromycin I 0.5 ⁇ g / fish peptide.
• Group 3 Oreochromycin I 1 ⁇ g / fish peptide.
• Group 4 Oreochromycin I Peptide 5 ⁇ g / fish.
• Group 5 Oreochromycin 1 10 ⁇ g / fish peptide.
• Group 6 Oreochromycin II Peptide 0.5 ⁇ g / fish.
• Group 7 Oreochromycin II Peptide 1 ⁇ g / fish.
• Group 8 Oreochromycin II Peptide 5 ⁇ g / fish.
• Group 9 Oreochromycin II Peptide 10 ⁇ / ⁇ .
• Group 10 Oreochromycin III 0 ⁇ g / fish peptide.
• Group 1 1 Oreochromycin III Peptide 1 ⁇ g / fish.
• Group 12 Oreochromycin III Peptide 5 ⁇ g ez.
• Group 13 Oreochromycin II1 Peptide 0 ⁇ g fish.
• a challenge test was performed, by intraperitoneal injection of the LD50 of A. hydrophila, and mortality was recorded for 7 days.
• the RPS was calculated as described above.
• the three peptides showed a dose-dependent effect and an RPS between 84% and 88%, compared to the group that received PBS that showed only 10% survival.
• the experimental groups were the following:
• Group 2 Oreochromycin I Peptide 0.01 mg / L.
• Group 3 Oreochromycin I Peptide 0.05 mg / L.
• Group 4 Oreochromycin I 0.1 mg / L peptide.
• Group 5 Oreochromycin I 0.5 mg / L peptide.
• Group 7 Oreochromycin II Peptide 0.05 mg / L.
• Group 8 Oreochromycin II peptide 0.1 mg / L.
• Group 9 Oreochromycin II Peptide 0.5 mg / L.
• Group 1 1 Oreochromycin III peptide 0.05 mg / L.
• Group 12 Oreochromycin III peptide 0.1 mg / L.
• Group 13 Oreochromycin III 0.5 mg / L peptide.
• a test was performed to determine the effect of each peptide, administered orally, as an additive in the feed, on the survival of the fish after a challenge with A. hydrophila. 130 tilapia (O. niloticus) of body mass of approximately 10 g were used, which were randomly distributed in thirteen experimental groups of ten animals each. Each peptide was administered at a concentration of 50, 250, 500 and 750 ⁇ g / kg of feed for 30 days.
• the experimental groups were the following:
• Group 2 Oreochromycin I Peptide 50 ⁇ g / Kg.
• Group 3 Oreochromycin I 250 ⁇ g / Kg peptide.
• Group 4 Oreochromycin I 500 ⁇ g / Kg Peptide.
• Group 5 Oreochromycin I 750 ⁇ g / Kg peptide.
• Group 6 Oreochromycin II Peptide 50 ⁇ g / Kg.
• Group 7 Oreochromycin II Peptide 250 ⁇ g Kg.
• Group 8 Oreochromycin II 500 ⁇ g / Kg peptide.
• Group 9 Oreochromycin II Peptide 750 ⁇ g / Kg.
• Group 10 Oreochromycin III Peptide 50 ⁇ / ⁇ ).
• Group 1 1 Oreochromycin III Peptide 250 ⁇ / Kg.
• Group 12 Oreochromycin III 500 ⁇ / ⁇ peptide.
• Group 13 Oreochromycin III Peptide 750 ⁇ 9 ⁇ 9.
• a challenge test was performed, by intraperitoneal injection of the LD50 of A. hydrophila, and mortality was recorded for 10 days.
• the RPS was calculated and, at 10 days after the challenge, the three peptides showed a dose-dependent effect and an RPS of between 80% and 95%, compared to the group that received PBS that showed only 13% survival.
• Example 5 Determination of resistance to infection by Staphylococcus aureus or Pseudomonas aeruginosa in mice
• Oreochromycin I and Oreochromycin II antimicrobial peptides were studied. Male mice (ICR) of 4 weeks of age and weighing 25 g were used in this test. The bacteria were grown in tryptone broth soybeans at 37 ° C for 8 h.
• the inoculums containing the amount of bacteria needed to produce between 90 and 100% of the mortality were prepared by diluting the cultures in PBS. The number of viable colonies was estimated based on the absorbance at 550 nm and was verified by plating serial dilutions of the inoculum. A dose of 4.5x10 6 and 1, 4x10 9 CFU / mouse was used depending on the microorganism tested and the route of administration.
• mice were infected per dose, and survival was monitored for 7-10 days after infection.
• mice received 0.5 ml of PBS (negative control) or PBS containing the selected antimicrobial peptide, by intraperitoneal injection, immediately after intraperitoneal administration of the bacteria.
• S. aureus was administered intravenously.
• the mice received 0.2 ml of PBS or PBS containing the antimicrobial peptides iv
• the Oreochromycin I and Oreochromycin II peptides administered intraperitoneally at a dose of 0.5 mg / kg of weight, reduce S. aureus and P. aeruginosa mortality by 90-100% in the control group 5-29% in the groups treated with the peptides.
• the mortality of 90-100% in the control group is reduced to 18- 40% in the groups treated with the peptides.
• Example 6 Activity of antimicrobial peptides against infection by an iridovirus
• EPC cells epidermaloma papulosum cyprinid
• EPC cells were incubated at 28 ° C, 5% C0 2 and 95% relative humidity, in RPMI-1640 medium containing 10% fetal bovine serum, 1 mM pyruvate, 2mM glutamine, 100 U / ml penicillin and 100 ⁇ g / ml streptomycin.
• the antimicrobial peptides of the present invention were amplified by PCR, using specific oligonucleotides that recognize the 5 'and 3' sequences of each of them, and were inserted into the pTargeT vector, to generate the plasmids pTargeT-Oreochromycin I, pTargeT-Oreochromycin II and pTargeT-Oreochromycin III.
• EPC cells were allowed to grow up to 90% confluence and transfected, transiently, with the vectors containing the genes encoding the antimicrobial peptides and with the empty pTargeT vector, at a DNA concentration of ⁇ g / mL, using lipofectamine 2000.
• the expression of antimicrobial peptides in transfected cells was analyzed by RT-PCR.
• the PCR products were visualized on a 2% agarose gel, stained with ethidium bromide.
• each well was washed 3 times with PBS and treated with various concentrations of Rana grylio virus (RGV).
• RGV Rana grylio virus
• the supernatants of each well were harvested, and frozen and thawed 3 times.
• serial dilutions of the supernatants were made in serum-free medium, and titrated on EPC cells. Each dilution was tested in triplicate. Data are represented as the mean ⁇ ES The differences between the groups were analyzed using an ANOVA and a Dunnett multiple comparisons test.
• LAL Limulus amebocyte lysate
• the antimicrobial peptides of the present invention have the ability to neutralize LPS in a dose-dependent manner.
• the EC50 of the Oreochromycin I, Oreochromycin II and Oreochromycin III peptides were 1, 23 ⁇ , 1, 41 ⁇ and 2.99 ⁇ , respectively.
• Example 8 Use of the Oreochromycin I, Oreochromycin II and Oreochromycin III antimicrobial peptides as molecular adjuvants
• tilapia (O. niloticus) each were formed.
• the weight of the tilapia was 50 g each, and injected intraperitoneally with PBS, formalin inactivated A. hydrophila cells and formalin inactivated hydrophila A cells, to which each of the peptides was added at a dose of ⁇ ⁇ g / fish. Injections were made on days 0 and 14. Blood was drawn from the caudal vein of the fish on days 0 and 21, and the serum was stored at - 20 ° C until use.
• hydrophila Titers of binding antibodies against A. hydrophila were determined by the 96-well plate agglutination assay. Serum dilutions (50 ⁇ ) were serially diluted in PBS, 50 ⁇ of formalin-inactivated A. hydrophila cells (4x10 9 cells / ml) were added to each well, and mixed thoroughly. The plates were incubated at room temperature, overnight, before examining the agglutination. Antibody titers are expressed as the reciprocal of the highest dilution of serum that gives agglutination positive.
• Example 9 Effect of co-immunization of ovalbumin (OVA) and the peptides Oreochromycin I, Oreochromycin II and Oreochromycin III on the humoral and cellular immune response in mice
• mice 24 female BALB / c mice were selected, with a body weight of 20 g, and separated into 4 test groups, of 6 animals each.
• the negative control group (PBS / OVA) was inoculated intraperitoneally, on days 0 and 7 with a dose of 6 ⁇ g of OVA in 0.2 mL of PBS.
• the groups treated with the peptides (PBS / OVA + peptide) were inoculated intraperitoneally, on days 0 and 7 with a dose of 6 g of OVA + 0.5 g of peptide in 0.2 mL of PBS.
• the animals were drawn and the total IgG titers were evaluated.
• mice with OVA co-administered with each of the peptides are presented in Figure 6.
• Animals of the PBS / OVA + peptide group showed a specific total IgG titer at OVA statistically higher than the control group. This behavior was maintained for all peptides.
• mice 64 male BALB / c mice, 6 weeks old, were selected and separated into 8 experimental groups of 8 mice each.
• the administration of the immunogens was performed by intraperitoneal injection in a volume of 0.1 mL.
• the peptides were administered in equimolar amounts (0,238x10 20 2,38x10 20 molecules and molecules).
• the experimental groups were the following:
• Group 1 Mice immunized with 1X PBS.
• Group 2 Mice immunized with OVA 5 ⁇ / ⁇ .
• Group 3 Mice immunized with OVA 5 ⁇ 9 / 3 ⁇ 3 ⁇ + Oreochromycin I 0.1 ⁇ 9 / 3 ⁇ 3 ⁇ , equivalent to 0.238x10 20 molecules / animal.
• Group 4 Mice immunized with OVA 5 + Oreochromicina I 1 ⁇ / ⁇ equivalent to 2,38x10 20 molecules / animal.
• Group 5 Mice immunized with OVA 5 ⁇ / ⁇ + Oreochromycin II 0.12 ⁇ 9 / 3 ⁇ 3 ⁇ , equivalent to 0.238x10 20 molecules / animal.
• Group 6 Mice immunized with OVA 5 ⁇ / ⁇ + Oreochromicina II 1, 2 ⁇ / ⁇ equivalent to 2,38x10 20 molecules / animal,
• Group 7 Mice immunized with OVA 5 ⁇ / ⁇ + Oreochromycin III 0.14 ⁇ 9 / 3 ⁇ 3 ⁇ , equivalent to 0.238x10 20 molecules / animal.
• Group 8 Mice immunized with OVA 5 + Oreochromycin III 1, 4 ⁇ / ⁇ , equivalent to 2.38x10 20 molecules / animal.
• the animals were immunized on days 0 and 14, and blood extractions were performed on days 0, 14 and 21.
• the animals' serum was used for the determination of the specific IgG total antibody titers, lgG1 and lgG2a.
• the spleen was removed from the mice to determine the cellular immune response against the OVA antigen.
• the spleen was removed under aseptic conditions, splenocytes were isolated and 2.5x10 5 cells were seeded at a cell concentration of 2x10 6 cells / mL in 96-well round-bottom plates.
• the cells were stimulated with Concanavalin A (5 ⁇ g / mL) or OVA (10 ⁇ g / mL) and incubated at 37 ° C, 5% C0 2 for 4 days. Culture supernatants were collected and used for the analysis, by ELISA, of the levels of interleukin-4 and interferon- ⁇ .
• the total IgG titers, lgG1 and lgG2a induced by immunization of mice with OVA co-administered with Oreochromycin I, II and III peptides are presented in Figure 7A and B.
• the animals of the PBS / OVA and PBS / OVA + Oreochromycin III groups also showed statistically higher total IgG titres at the dose of 1.4 ⁇ g / animal (p ⁇ 0.05).
• Splenocyte culture supernatants, stimulated with OVA, from the immunized animals of each group were analyzed by ELISA to measure the concentration of IFN- ⁇ and IL-4.
• the highest levels of IFN- ⁇ secretion are obtained in animals immunized with OVA co-administered with the Oreochromycin III peptide in a dose-dependent manner. These levels were significantly higher than the levels obtained in splenocytes from animals immunized with PBS or OVA alone (p ⁇ 0.001).
• IFN- ⁇ secretion levels in animals immunized with OVA co-administered with the Oreochromycin II peptide at a dose of 1.2 ⁇ g / animal were significantly higher than the levels obtained in splenocytes from animals immunized with PBS. or OVA alone (p ⁇ 0.05) ( Figure 8). No secretion of IL-4 was observed in any of the groups under the experimental conditions employed.
• Example 10 Effect of co-immunization of the MY32 antigen and the Oreochromycin I peptide on the humoral immune response in tilapia
• tilapia O. niloticus
• the route of administration was intraperitoneal, the immunogen was applied in an injection volume of 0.3 mL.
• the experimental groups were:
• Group 1 Fish immunized with PBS.
• Group 2 Fish immunized with the MY32 protein at a dose of 1 ⁇ g / g body weight.
• Group 3 Fish immunized with the MY32 protein at a dose of 1 ⁇ g / g body weight co-administered with 10 ⁇ g / fish of the Oreochromycin I peptide.
• Group 4 Fish immunized with the MY32 protein at a dose of 1 ⁇ ⁇ of body weight co-administered with 1 ⁇ / fish of the Oreochromycin I peptide, all adjuvant in Montanide 888.
• Group 5 Fish immunized with the MY32 protein at a dose of 1 ⁇ ⁇ of body weight co-administered with 10 ⁇ / fish of the Oreochromycin I peptide, all adjuvant in Montanide 888.
• Group 6 Fish immunized with My32 protein at a dose of 1 ⁇ 9 ⁇ adjuvant body weight in Montanide 888.
• mice were immunized on days 0 and 14, and blood extractions were performed on days 0, 14, 21 and 28. The animals' serum was used for the determination of specific IgM antibody titers.
• Figure 9 shows the IgM titres induced by the immunization of the fish with the MY32 antigen co-administered with the Oreochromycin I peptide.
• the animals of the MY32 + Oreochromycin I group at a dose of 10 ⁇ g / animal, adjuvated in Montanide 888, they showed a specific IgM titer to MY32 statistically superior to the groups immunized with PBS, MY32, and MY32 co-administered with the Oreochromycin I peptide at a dose of 1 ⁇ g / fish (p ⁇ 0.05) ( Figure 9 ). No significant differences were observed between the rest of the experimental groups.

Landscapes

• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Zoology (AREA)
• Medicinal Chemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• General Health & Medical Sciences (AREA)
• Polymers & Plastics (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Immunology (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Gastroenterology & Hepatology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Genetics & Genomics (AREA)
• Toxicology (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• Food Science & Technology (AREA)
• Animal Husbandry (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Marine Sciences & Fisheries (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Virology (AREA)
• Peptides Or Proteins (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Fodder In General (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)

Priority Applications (12)

Applications Claiming Priority (2)

Publications (1)

Family

ID=47143463

Family Applications (1)

Country Status (16)

Cited By (1)

Families Citing this family (3)

Citations (1)

Family Cites Families (14)

• 2011
  • 2011-09-30 CU CU20110181A patent/CU24076B1/es active IP Right Grant
• 2012
  • 2012-09-27 AR ARP120103606A patent/AR088176A1/es unknown
  • 2012-10-01 ES ES12783080.0T patent/ES2600903T3/es active Active
  • 2012-10-01 JP JP2014532244A patent/JP6034385B2/ja active Active
  • 2012-10-01 CA CA2849040A patent/CA2849040C/en active Active
  • 2012-10-01 MX MX2014003892A patent/MX348934B/es active IP Right Grant
  • 2012-10-01 US US14/346,562 patent/US9549978B2/en active Active
  • 2012-10-01 EP EP12783080.0A patent/EP2767290B1/en not_active Not-in-force
  • 2012-10-01 BR BR112014007491-7A patent/BR112014007491B1/pt active IP Right Grant
  • 2012-10-01 CN CN201280050943.4A patent/CN103874502B/zh active Active
  • 2012-10-01 RU RU2014117659A patent/RU2636001C2/ru active
  • 2012-10-01 AU AU2012315083A patent/AU2012315083B2/en not_active Ceased
  • 2012-10-01 WO PCT/CU2012/000005 patent/WO2013044890A1/es not_active Ceased
  • 2012-10-01 KR KR1020147009805A patent/KR101986358B1/ko active Active
• 2014
  • 2014-03-24 ZA ZA2014/02171A patent/ZA201402171B/en unknown
  • 2014-03-27 CL CL2014000760A patent/CL2014000760A1/es unknown

Patent Citations (1)

Non-Patent Citations (16)

Also Published As

Similar Documents

Legal Events